Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2006-09-12
2006-09-12
Kemmerer, Elizabeth (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C514S002600, C514S012200, C530S303000
Reexamination Certificate
active
07105167
ABSTRACT:
IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16, 25, 49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder.
REFERENCES:
patent: 5077276 (1991-12-01), Ballard et al.
patent: 5106832 (1992-04-01), Froesch et al.
patent: 5164370 (1992-11-01), Ballard et al.
patent: 5273961 (1993-12-01), Clark
patent: 5470828 (1995-11-01), Ballard et al.
patent: 5473049 (1995-12-01), Obermeier et al.
patent: 5514646 (1996-05-01), Chance et al.
patent: 5565428 (1996-10-01), Clark et al.
patent: 5714460 (1998-02-01), Gluckman et al.
patent: 5741776 (1998-04-01), Clark et al.
patent: 5750373 (1998-05-01), Garrard et al.
patent: 5821047 (1998-10-01), Garrard et al.
patent: 5834250 (1998-11-01), Wells et al.
patent: 5891722 (1999-04-01), Fuks et al.
patent: 5985830 (1999-11-01), Acott et al.
patent: 5994303 (1999-11-01), Arrhenius-Nyberg et al.
patent: 6403764 (2002-06-01), Dubaquie et al.
patent: 6506874 (2003-01-01), Dubaquie et al.
patent: 6509443 (2003-01-01), Dubaquie et al.
patent: 2003/0191065 (2003-10-01), Dubaquie et al.
patent: 2004/0023883 (2004-02-01), Dubaquie et al.
patent: 2004/0033951 (2004-02-01), Dubaquie et al.
patent: 2004/0033952 (2004-02-01), Dubaquie et al.
patent: 128733 (1984-12-01), None
patent: 214826 (1987-03-01), None
patent: 230869 (1987-08-01), None
patent: 288451 (1988-10-01), None
patent: 294021 (1988-12-01), None
patent: 369943 (1990-05-01), None
patent: 742228 (1996-11-01), None
patent: 965596 (1999-12-01), None
patent: 0 704 527 (2003-05-01), None
patent: WO 89/05822 (1989-06-01), None
patent: WO 89/08667 (1989-09-01), None
patent: WO 89/09268 (1989-10-01), None
patent: WO 89/09792 (1989-10-01), None
patent: WO 94/04569 (1994-03-01), None
patent: WO 96/33216 (1996-10-01), None
patent: WO 96/37216 (1996-11-01), None
patent: WO 97/39032 (1997-10-01), None
patent: WO 98/11913 (1998-03-01), None
patent: WO 98/45427 (1998-10-01), None
patent: WO 98/56406 (1998-12-01), None
patent: WO 99/32620 (1999-07-01), None
patent: WO 00/20023 (2000-04-01), None
patent: WO 00/23469 (2000-04-01), None
patent: WO 00/69901 (2000-11-01), None
Singri et al. Acute renal failure. J Am Med Assoc 289(6):747-751, 2003.
Dubaquie et al. Binding protein-3-selective insulin-like growth factor 1 variants: engineering, biodistributions, and clearance. Endocrinology. 142(1):165-173, 2001.
Wolk et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst. 90(12):911-915, 1998.
Chan et al. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science. 279(5350):563-566, 1998.
Hankison et al. Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet. 351(9113):1393-1396, 1998.
Barnett and Owens, “Insulin analogues”Lancet349 (9044): 47-51 (Jan. 4, 1997).
Bass et al., “Hormone Phage: An Enrichment Method for variant proteins with altered binding properties”,Proteins : Structure, Function, and Genetics8 (4): 309-314 (1990).
Baxter & Martin, “Binding Proteins For Insulin-Like Growth Factors In Adult Rat Serum. Comparison With Other Human and Rat Binding Proteins”Biochem&Biophys Res. Comm.147(1):408-415 (1987).
Baxter, R., “The Insulin-Like Growth Factors and Their Binding Proteins”Comp. Biochem, Physiol.91B(2): 229-235 (1988).
Binkert et al., “Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2)”EMBO Journal8: 2497-2502 (1989).
Bornfeldt et al., “Binding and biological effects of insulin, insulin analogues and insulin-like growth factor in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities”Diabetologia34(5): 307-313 (May 1991).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”Science247: 1306-1310 (1990).
Brange et al., “Designing insulin for diabetes therapy by protein engineering”Current Opinion in Structural Biology1: 934-940 (1991).
Brange et al., “Monomeric insulins obtained by protein engineering and their medical implications”Nature333 (6174) : 679-682 (Jun. 16, 1988).
Brange, J., “Insulin Preparations”Galenics of Insulin, The Physico-Chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations, New York: Springer-Verlag, pp. 17-40 (1987).
Brenner, S.E., “Errors in Genome Annotation”Trends in Genetics15: 132-133 (1999).
Brewer et al., “Cloning, Characterization, and Expression of a Human Insulin-Like Growth Factor Binding Protein”Biochem&Biophys. Res. Comm.152(3): 1289-1297 (1988).
Brinkman et al., “Isolation and Characterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1)”The EMBO J.7:2417-2423 (1988).
Cara et al., “An insulin-like growth factor I/insulin hybrid exhibiting high potency for interaction with the type I insulin-like growth factor and insulin receptors of placental plasma membranes”Journal of Biological Chemistry265 (29):17820-17825 (Oct. 15, 1990).
Chang et al., “Single-Step Solubilzation and Folding of IGF-1 Aggregates FromEscherichia coli” Protein Folding: In Vivo and In Vitro, American Chemical Society, Chapter 14, pp. 178-188 (1993).
Clackson et al., “A Hot Spot of Binding Energy in a Hormone-Receptor Interface”Science267: 383-386 (1995).
Cunningham et al., “Engineering Human Prolactin to Bind to the Human Growth Receptor”Science247:1461-1465 (1990).
DiCera, E., “Site-Specific Thermodynamics: Understanding Cooperativity in Molecular Recognition”Chem. Rev.98: 1563-1591 (1998).
DiMarchi et al., “Synthesis of a fast—acting insulin analog based on structural homology with insulin-like growth factor-I”Peptides: Chemistry and Biology(Proceedings of the Twelfth American Peptide Symposium) J.A. Smith and J.E. River, eds., Leiden: ESCOM pp. 26-28 (1992).
Dodd et al., “Reversible Adsorption of soluble hexameric insulin onto the surface of insulin crystals cocrystallized with protamine: an electostatic interaction”Pharmaceutical Research12(1):60-68 (Jan. 1995).
Drejer, K., “The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake”Diabetes-Metabolism Reviews8(3): 259-285 (Oct. 1992).
Hober et al., “Disulfide Exchange Folding of Insulin-Like Growth Factor I”Biochemistry31: 1749-1756 (1992).
Howey et al., “[Lys(B28), Pro(B29)]-Human Insulin: an Equipotent Analog of Human Insulin with Rapid Onset and Short Duration of Action”Diabetes(Abstract #1688) 40(Suppl 1): 423A (1991).
Hua, Qing-Hua et al., “Mini-proinsulin and Mini-IGF-I: Homologous Protein Sequence Encoding Non-homologous Structures”JBM277:103-118 (1998).
Kang et al., Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, Glu B27; Asp B10, Asp B28) on meal-related plasma glucose excursions in type I diabetic subjects:Diabetes Care14(7): 571-577 (Jul. 1991).
Kelley et al., “Analysis of the Factor VIIa Binding Site on Human Tissue Factor: Effects of Tissue Factor Mutations on the Kinetics and Thermodynamics of Binding”Biochemistry34(33): 10383-10392 (1995).
Kunkel et al., “Efficient site-directed mutagenesis using uracil-containing DNA”Methods in Enzymology240: 125-139 (1991).
Lassalle et al., “ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines”Journal of Biological Chemistry271: 20458-20464 (1996).
Leung et al., “Growth hormone receptor and serum binding protein: purification, cloning and expression”Nature330:537-543 (1987).
Lowman et al., “Selecting High-Affinity Binding Proteins by Monovalent Phage Display”
Dubaquie Yves
Fielder Paul J.
Lowman Henry B.
Mortensen Deborah L.
Barnes Elizabeth M.
Bunner Bridget E.
Dreger Ginger R.
Genentech Inc.
Kemmerer Elizabeth
LandOfFree
Methods for treating clinical manifestations of GH/GF axis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating clinical manifestations of GH/GF axis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating clinical manifestations of GH/GF axis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3613901